Fair Market Value in Clinical Research: The Myths and the Realities
Presented by: Norman M. Goldfarb, CRCP
In this eye-opening webinar, Norman M. Goldfarb, MAGI Chairman and Editor of the Journal of Clinical Research Best Practices, will explain what FMV really means. Study sponsors and CROs have good reasons to pay clinical research sites fairly. Likewise, clinical research sites have good reasons to charge sponsors and CROs fairly. The problem is that the concept of fair market value (FMV) is widely misunderstood, to the disadvantage of all parties.
- Define "fair market value" correctly.
- Explain how FMV is currently applied incorrectly to study budgets.
- Explain how FMV should be applied correctly to study budgets.
Access Webinar Now!
About the Presenter
Norman M. Goldfarb, CRCP, is Managing Director of First Clinical Research LLC, a provider of clinical research best practices information services. He is also Chairman of MAGI, a broadly-based organization he founded in 2003. With over 10,000 members representing clinical research sponsors, sites and CROs, MAGI is streamlining clinical research by standardizing best practices for clinical operations, business and regulatory compliance. Mr. Goldfarb is Editor of the Journal of Clinical Research Best Practices, with over 100,000 subscribers. He previously founded and led eight companies, including Calgene, the leading agricultural biotechnology company in the 1980s. He has an M.B.A. degree from Stanford University and a B.A. degree in Economics from Yale University. He has authored or presented over 1,000 articles and talks on clinical research. His influence is indicated by 30,000 clinical research LinkedIn connections, #1 in the industry. In 2016, PharmaVoice Magazine honored him as one of the 100 most inspiring people in the pharmaceutical industry. In 2017, ACRP honored him with its award for innovation.